You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 白雲山(0874.HK)高開3.11% 子公司收到有關磷酸氯喹片的藥品補充申請批件
格隆匯 02-18 09:28
格隆匯2月18日丨白雲山(0874.HK)高開3.11%,報26.5港元,暫成交259.7萬港元,最新總市值430億港元。白雲山昨晚公佈,2月17日,公司控股子公司光華藥業收到廣東省藥監局核准簽發的磷酸氯喹片《藥品補充申請批件》,該批件僅在疫情期間內有效。光華藥業獲得藥品補充申請批件後,將迅速恢復磷酸氯喹片生產,並經廣東省藥檢所檢驗合格後上市。近日,科技部生物中心副主任孫燕榮表示,療效專家組經過認真細緻的研討,一致認為磷酸氯喹是一個上市多年的老藥,用於廣泛人羣治療的安全性是可控的。基於前期臨牀機構所開展的臨牀研究,結果可以明確磷酸氯喹治療新冠肺炎具有療效。應當儘快將磷酸氯喹納入到新一版的診療指南,擴大臨牀適用範圍。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account